G

Grifols SA
D

GRFS

9.01500
USD
0.16
(1.81%)
Market Open
Volume
27,262
EPS
1
Div Yield
-
P/E
34
Market Cap
6,133,888,073
Related Instruments
ALNY
ALNY
-0.56
(-0.18%)
307.44 USD
AMGN
AMGN
1.31
(0.44%)
296.46 USD
AZN
AZN
-0.715
(-0.96%)
73.730 USD
BMY
BMY
-1.225
(-2.46%)
48.535 USD
GSK
GSK
-0.305
(-0.75%)
40.535 USD
ICLR
ICLR
0.230
(0.16%)
145.950 USD
NVO
NVO
-2.830
(-3.54%)
77.190 USD
PFE
PFE
-0.200
(-0.82%)
24.355 USD
SNY
SNY
-0.210
(-0.42%)
49.480 USD
TAK
TAK
-0.115
(-0.76%)
15.090 USD
More
News

Title: Grifols SA

Sector: Healthcare
Industry: Drug Manufacturers - General
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.